A diagnosis of breast cancer, the most common cancer worldwide, is life changing for patients, their families and loved ones. Listening and learning from their real-life experiences is key. We are working on improving access to and participation by patient populations who are often underrepresented in clinical trials, identifying new pathways or mutations that may play a role in disease progression and developing therapies with a goal of extending and improving the lives of those with breast cancer.
More men are receiving a diagnosis of prostate cancer than ever before. At Novartis, we are harnessing the innovation of our world-class scientists, strategic partnerships, and one of the industry’s most competitive pipelines to make the promise of next-generation medicines a reality to address unmet needs in care.
Globally, more than 2 million people are diagnosed with lung cancer each year, and each one has a unique experience that must be considered. Through cutting-edge science and technology, we are finding new ways to explore therapies with a goal of improving outcomes for each individual with lung cancer.
Innovative therapies introduced over the past two decades have revolutionized treatment for people with CML, a serious and life-threatening blood disorder. Even with the innovations seen in this space, some patients still experience resistance and/or intolerance to currently available therapies, which means that CML can remain a devastating diagnosis. More work needs to be done to turn scientific breakthroughs into medicines so that more people can benefit from life-changing medicines.
Even though neuroendocrine tumors (NETs) are considered slow-growing malignancies, people with this type of cancer can experience rapid progression and poor prognosis. In many cases, diagnosis is delayed until patients have advanced disease, often making the impact of the disease more devastating. Even though NETs are considered rare, the number of people affected has grown over 500% in the last three decades, reinforcing the need for innovative treatment options for those who are newly diagnosed with inoperable or advanced cancer.

Facing the fear of breast cancer recurrence

When you think of the word ‘cancer’, what are the first words that spring to mind?

Prostate cancer and support of the care partner – Carl and Arlene’s story - Let’s Talk About The C-Word

Helping people solve problems

Let’s Talk About The C-Word
Novartis commits to addressing racial disparities in breast cancer screening, treatment and care
Resource links
Hematology
Events and scientific meetings
AACR | American Association for Cancer Research | https://www.aacr.org/ |
ASCO | American Society of Clinical Oncology | https://www.asco.org/ |
ASCO GI | American Society of Clinical Oncology, Gastrointestinal Cancers | https://meetings.asco.org/meetings/2024-gastrointestinal-cancers-sympos… |
ASCO GU | American Society of Clinical Oncology, Genitourinary Cancers | https://meetings.asco.org/meetings/2024-genitourinary-cancers-symposium… |
ASH | American Society of Hematology | https://www.hematology.org/ |
AUA | American Urological Association | https://www.auanet.org/ |
EANM | European Association of Nuclear Medicine | https://www.eanm.org/ |
EAU | European Association of Urology | https://uroweb.org/ |
EHA | European Hematology Association | https://ehaweb.org/ |
EMBT | Formerly the European Society for Blood and Marrow Transplantation | https://www.ebmt.org/ |
ENETS | European Neuroendocrine Tumor Society | https://www.enets.org/ |
ASMOIASLC | European Society For Medical Oncology International Association of the Study of Lung Cancer | https://www.esmo.org/meeting-calendar/past-meetings/european-lung-cance… |
SABCS | San Antonio Breast Cancer Symposium | https://www.sabcs.org/ |
Other therapeutic areas

Cardiovascular, renal and metabolic

Immunology
